sp-3164
salarius pharma
['lymphoma', 'hodgkin', 'sp-3164', 'salarius']
our preclinical findings show significant anticancer activity of sp-3164 in non-hodgkin lymphoma models. daniela santiesteban, phd, will present the exciting data at 's 2023 annual meeting. we d love to see you there! abstract: #aacr23
Salarius is a cancer-focused biotechnology company. Currently in clinical trials for Ewing Sarcoma w/ Orphan Drug & Rare Pediatric Disease Designation.